Health
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study – BioPharma-Reporter.com
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The novel nasal spray, INNA-051, is being developed by Australian biotech Ena Respiratory. The company has published its animal study, led by Public Health Englands Deputy Director Professor Miles Carroll, on biomedical pre-publication research site medRxiv.
The researchers note that INNA-051 significantly reduced COVID-19 virus levels in the nose and throat. A nasal administration delivered once or twice a week could be used to prevent infection in at-risk populations and healthcare workers, s…
-
Noosa News23 hours agoPCBA reviews DMP | Noosa Today
-
Noosa News23 hours ago‘So cheap’: Where you can get an Ascot house for half the price
-
Noosa News22 hours agoFemale farmers determined to defy NSW dairy industry exodus
-
Business22 hours agoThese 3 Aussie stocks could skyrocket and stay there for decades